|
Market Cap (22-May) $1,644,114,176 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 75.19 |
EPS 1.09 |
NEU released this announcement to the ASX on 16 February 2021, 9:23. The announcement is marked as price sensitive, and is 5 page(s) in length and 225kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.163% short sold according to ASIC data. It was ranked the 380th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline | 16 February 2021, 9:23 |
| Successful Phase 1 trial for Neuren's NNZ-2591 | 15 February 2021, 9:36 |
| Quarterly report and cash flow statement for Q4 2020 | 29 January 2021, 10:13 |
| European Commission grants 3 NNZ-2591 Orphan designations | 11 January 2021, 9:34 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 